Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
2024

Genomic Instability Patterns in Ovarian Cancer Patients Treated with Olaparib

Sample size: 2147 publication 10 minutes Evidence: high

Author Information

Author(s): Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, Karen Cadoo, Fiona Simpkins, Carol Aghajanian, Alexandra Leary, Andrés Poveda, Stephanie Lheureux, Eric Pujade-Lauraine, Benoit You, Jonathan Ledermann, Ursula Matulonis, Charlie Gourley, Kirsten M. Timms, Zhongwu Lai, Darren R. Hodgson, Cathy E. Elks, Simon Dearden, Coumaran Egile, Pierre Lao-Sirieix, Elizabeth A. Harrington, Jessica S. Brown

Primary Institution: AstraZeneca, Cambridge Biomedical Campus, UK

Hypothesis

What are the patterns and potential causes of genomic instability in ovarian cancer patients treated with olaparib?

Conclusion

The study provides insights into genomic instability patterns in ovarian cancer, highlighting the role of BRCA mutations and other factors in treatment response.

Supporting Evidence

  • BRCAm tumors had significantly higher genomic instability scores than non-BRCAm tumors.
  • 47.6% of tumors analyzed were found to have BRCAm.
  • High biallelic loss was observed in 97.3% of BRCAm tumors.
  • Median genomic instability scores varied significantly across different mutation statuses.
  • Non-BRCA HRRm tumors showed variable genomic instability patterns.

Takeaway

This study looked at over 2000 ovarian cancer patients to see how their tumors change and how that affects treatment with a drug called olaparib.

Methodology

The study analyzed genomic data from six clinical trials using next-generation sequencing to assess homologous recombination deficiency and genomic instability scores.

Potential Biases

Potential biases due to the selection criteria of the trials and the lack of methylation data in some studies.

Limitations

The study pooled data from different trials with variations in design and patient selection, which may affect the results.

Participant Demographics

The study included patients with high-grade serous or endometrioid ovarian cancer, with a significant proportion being BRCAm.

Statistical Information

P-Value

<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/s13073-024-01413-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication